10q10k10q10k.net
SOLENO THERAPEUTICS INC

SOLENO THERAPEUTICS INCSLNOEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

Top Holders

Holder% OwnedSharesChangeAs of
Vivo16.20%
6.3M
—2024-09-05
S.S. OR10.50%
4.1M
▲ +0.40pp2024-11-14
The9.99%
4.0M
—2024-09-10
Nantahala Capital Management, LLC9.90%
3.1M
—2024-02-14
Adage Capital Management, L.P.8.55%
3.3M
—2024-11-12
Adage Capital Partners, L.P.5.99%
1.8M
▼ -2.70pp2024-02-07
Avoro Capital Advisors LLC5.60%
2.2M
—2024-11-14
BlackRock, Inc.5.20%
2.0M
—2024-10-24
The Carlyle Group Inc.4.99%
2.0M
▼ -1.21pp2024-10-21
Perceptive Advisors LLC4.10%
1.8M
▼ -4.70pp2024-11-19
Commodore2.30%
700.0K
—2024-02-14

Insider Transactions

Net 90d: −$429.3K · buys $0 / sells $429.3K
Range:
Action:
Role:
InsiderRoleAction
2026-03-27Huang Michael F.Sr. VP of Clinical DevelopmentSell (open market)
4.3K
$30.04$127.8K
2026-03-27Huang Michael F.Sr. VP of Clinical DevelopmentSell (open market)
1.8K
$31.04$57.0K
2026-03-27Huang Michael F.Sr. VP of Clinical DevelopmentSell (open market)
488
$31.72$15.5K
2026-03-27Meredith ManningChief Commercial OfficerSell (open market)
4.9K
$30.04$146.1K
2026-03-27Meredith ManningChief Commercial OfficerSell (open market)
2.1K
$31.04$65.2K
2026-03-27Meredith ManningChief Commercial OfficerSell (open market)
558
$31.72$17.7K
2026-03-02Jennifer FulkCHIEF FINANCIAL OFFICERGrant
39.2K
$0.00$0
1–7 of 7